Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Case report: reinitiating pembrolizumab treatment after small bowel perforation

Fig. 1

Consideration of PD-L1 and/or tumor-mutation burden in clinical trials of immune checkpoint inhibitors in non-small cell lung cancer. Shown are response rates, progression free survival (PFS) and overall survival (OS) based on PD-L1 expression levels and/or tumor-mutation burden for twelve published clinical trials (See Supplemental Materials for complete references). The x-axis indicates tumor mutation burden and/or percentage of PD-L1 positive cells (tumor cells unless otherwise indicated). HNS = high nonsynonymous # of mutations (median of 324), LNS = low nonsynonymous # of mutations (median of 122), HE = high exonic # of mutations (median of 494), LE = low exonic # of mutations (median of 190); Q3W = 10 mg/kg of pembrolizumab every 3-weeks, Q2W = 10 mg/kg of pembrolizumab every 2-weeks; TC0 (percent of PD-L1 positive tumor cells, < 1%) or IC0 (percent of PD-L1 positive tumor-infiltrating immune cells, < 1%), TC1 (≥1 and < 5%) or IC1 (≥1 and < 5%), TC2 (≥5 and < 50%) or IC2 (≥5 and < 10%), TC3 (≥50%) or IC3 (≥10%); 1Q12W = ipilimumab every12-weeks, 1Q6W = ipilimumab every 6-weeks; HTB = high tumor-mutational burden (≥243 somatic missense mutations), L/MTB = low/medium tumor-mutation burden (low = < 100 somatic missense mutations; medium = 100–242 somatic missense mutations)

Back to article page